Chronic pain and depression: A review

Roy, Ranjan; Thomas, Michael R.; Matas, Manuel

doi:10.1016/0010-440x(84)90027-0

Cited by 86 publications

(41 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Since the beginning of chronic pain research there has been the perception that depression is commonly associated with chronic pain and CPPs [12][13][14][15][16][17]. Until recently, however, it was still debated whether this association was real.…”

mentioning

confidence: 99%

Comorbidity between psychiatric disorders and chronic pain

Fishbain

Cutler

Rosomoff

et al. 1998

Current Review of Pain

View full text Add to dashboard Cite

mentioning

confidence: 99%

Comorbidity between psychiatric disorders and chronic pain

Fishbain

Cutler

Rosomoff

et al. 1998

Current Review of Pain

View full text Add to dashboard Cite

“…SF-36 measures pain-related behavior, whereas VAS measures pain, and in the present study, the use of thicker (21 and 23 gauge) needles was found to be more effective at improving behavioral dysfunction. Furthermore, depression commonly coexists in patients with chronic pain (16%-90%), [33][34][35] and it has been reported that SF-36 reflects depression severity in these patients. 36,37 Accordingly, we postulate that thicker needles also alleviate chronic pain-related behavioral dysfunction and depression.…”

Section: Discussionmentioning

confidence: 99%

Comparison of 3 Needle Sizes for Trigger Point Injection in Myofascial Pain Syndrome of Upper- and Middle-Trapezius Muscle: A Randomized Controlled Trial

Rah

Sheen

et al. 2009

Archives of Physical Medicine and Rehabilitation

View full text Add to dashboard Cite

Objectives: To investigate (1) the relation between needle diameter and treatment efficacy of myofascial pain syndrome and (2) the relation between needle diameter and pain intensity during injection.Design: Randomized controlled trial. Setting: University-affiliated tertiary-care hospital. Participants: Volunteers (Nϭ77) with myofascial pain syndrome affecting upper-and middle-trapezius muscles with at least 3 months' duration of pain.Intervention: Participants were randomly assigned to receive trigger point injections on 1 side of the trapezius with a 21-, 23-, or 25-gauge needle. After a 1-time injection, participants were followed up for 14 days. Participants and the assessor were blinded for group assignment.Main Outcome Measures: Treatment efficacy was measured with the visual analog scale (VAS; at pretreatment, and posttreatment on days 1, 4, 7, 14) for neck and upper-back pain, the Neck Disability Index (NDI; at pretreatment, and posttreatment on days 7, 14), and the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36, at pretreatment and posttreatment on days 7, 14) for health-related quality of life. Pain intensity during injection was evaluated immediately after injection with VAS.Results: VAS scores for posttreatment on days 4, 7, and 14 decreased significantly compared with pretreatment scores in all groups; NDI scores on days 7 and 14 decreased significantly compared with pretreatment scores in all groups; SF-36 scores on days 7 and 14 decreased significantly compared with pretreatment scores in the 21-and 23-gauge needle groups; and SF-36 score on day 14 showed significant difference between the 21-and 25-gauge needle groups. For pain intensity during injection, VAS scores indicated no significant difference between the 3 groups. Conclusions:No difference between the needle types was observed in terms of VAS or NDI, or in terms of pain intensity felt by patients during injection. In terms of SF-36 scores, injections with 21-or 23-gauge needles were found to be more effective. However, a well-controlled investigation is needed to explore the effect of needle thickness on health-related quality of life.

show abstract

“…Indeed, extensive research shows that depression is a common affective concomitant of chronic pain, and that this population experiences more depression than do individuals without pain (Banks and Kerns 1996;Fishbain et al 1997;Gatchel 2005;Hanson and Gerber 1990;Magni 1987;Romano and Turner 1985;Roy et al 1984;Turk and Stieg 1987). Moreover, a growing body of evidence suggests that anger has been underestimated for its role in the affective distress of chronic pain patients.…”

Section: Affective Consequences Of Lossmentioning

confidence: 96%

Primary, Secondary, and Tertiary Losses in Chronic Pain Patients

Worzer

Kishino²,

Gatchel

2009

Psychol. Inj. and Law

View full text Add to dashboard Cite

Treating individuals with chronic illness and disability requires attention to physical, psychological, and social factors. These unique challenges are optimally addressed by utilizing a biopsychosocial approach, while considering the potential array of both gains and losses that chronic pain patients experience. The benefits a patient receives from remaining ill are often referred to as secondary gain. In medicolegal settings, a common example of a secondary gain issue is the effort to obtain financial compensation. While secondary gain can be one factor that contributes to perpetuating illness and disability, there are often more powerful losses that lead to such perpetuation. The losses associated with pain and disability are not frequently discussed. The overall purpose of this paper is to identify primary, secondary, and tertiary loss issues in chronic pain patients, and address issues related to how these factors are important within a medicolegal/forensic context.

show abstract

Chronic pain and depression: A review

Cited by 86 publications

References 35 publications

Comorbidity between psychiatric disorders and chronic pain

Comorbidity between psychiatric disorders and chronic pain

Comparison of 3 Needle Sizes for Trigger Point Injection in Myofascial Pain Syndrome of Upper- and Middle-Trapezius Muscle: A Randomized Controlled Trial

Primary, Secondary, and Tertiary Losses in Chronic Pain Patients

Contact Info

Product

Resources

About